AMRN - Amarin Corporation PLC

AMRN - Amarin Corporation PLC

https://www.amarincorp.com

Momentum: Bearish

Recent News

Powered by Alpha Vantage

Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid ( EPA ) at ESC 2025

GlobeNewswire • 2 weeks, 1 day ago • score: 0.12

-- Data Further Advance Understanding of VASCEPA®/VAZKEPA® Potential Mechanisms of Action -- -- Data Further Advance Understanding of VASCEPA®/VAZKEPA® Potential Mechanisms of Action ...

Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid ( EPA ) at ESC 2025 - Amarin Corp ( NASDAQ:AMRN )

Benzinga • 2 weeks, 1 day ago • score: 0.11

DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 31, 2025 ( GLOBE NEWSWIRE ) -- AMRN today highlighted in vitro data assessing the effects of EPA on lipoprotein ( a ) [Lp ( a ) ] oxidation and on cellular stress and inflammatory protein expression in endothelial cells and preliminary data showcasing ...

New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology ( ESC ) Congress 2025

GlobeNewswire • 3 weeks ago • score: 0.13

DUBLIN and BRIDGEWATER, N.J., Aug. 25, 2025 ( GLOBE NEWSWIRE ) -- Amarin Corporation plc ( NASDAQ:AMRN ) today announced upcoming presentations at the European Society of Cardiology ( ESC ) Congress 2025, August 29th-September 1st, in Madrid, Spain, where new data will further illuminate the ...

Is Amarin ( AMRN ) Stock Outpacing Its Medical Peers This Year?

Zacks Commentary • 3 weeks, 3 days ago • score: 0.43

Here is how Amarin (AMRN) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Amarin Corporation plc, a pharmaceutical company, is engaged in the development and commercialization of therapies for the treatment of cardiovascular disease in the United States. The company is headquartered in Dublin, Ireland.

52W High

$17.49

52W Low

$7.08

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.78

Valuation

Rich

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

500.00

EV/EBITDA (<8 favorable)

-5.80

EV/Revenue (<3 favorable)

0.12

P/S (TTM) (<3 favorable)

1.45

P/B (<3 favorable)

0.68

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

1.88%

Institutions (25–75% balanced)

18.34%

Shares Outstanding

20,682,800

Float

373,903,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

219,361,000

Gross Profit (TTM)

118,674,000

EPS (TTM)

-5.00

Profit Margin (>10% good)

-0.47%

Operating Margin (TTM) (higher better)

0.09%

ROE (TTM) (>15% strong)

-0.20%

EPS YoY (Quarterly) (>10% good)

-0.94

Revenue YoY (Quarterly) (>8% good)

0.08

Momentum

Bearish momentum

Value

-0.1140

Previous

-0.1095

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025